Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Thioredoxin and hematologic malignancies.

Publication ,  Journal Article
An, N; Kang, Y
Published in: Adv Cancer Res
2014

Thioredoxin (Trx) is an inflammation-inducible small oxidoreductase protein ubiquitously expressed in all organisms. Trx acts both intracellularly and extracellularly and is involved in a wide range of physiological cellular responses. Inside the cell, Trx alleviates oxidative stress by scavenging reactive oxygen species (ROS), regulates a variety of redox-sensitive signaling pathways as well as ROS-independent genes, and exerts cytoprotective effects. Outside the cell, Trx acts as growth factors or cytokines and promotes cell growth and many other cellular responses. Trx is also implicated in tumorigenesis. Trx is a proto-oncogene and is overexpressed in many cancers and correlates with poor prognosis. Trx stimulates cancer cell survival, promotes tumor angiogenesis, and inhibits both spontaneous apoptosis and drug-induced apoptosis. Inhibitors targeting Trx pathway provide a promising therapeutic strategy for cancer prevention and intervention. More recently, data from our laboratory demonstrate an important role of Trx in expanding long-term repopulating hematopoietic stem cells. In this chapter, we first provide an overview of Trx including its isoforms, compartmentation, and functions. We then discuss the roles of Trx in hematologic malignancies. Finally, we summarize the most recent findings from our lab on the use of Trx to enhance hematopoietic reconstitution following hematopoietic stem cell transplantation.

Duke Scholars

Published In

Adv Cancer Res

DOI

EISSN

2162-5557

Publication Date

2014

Volume

122

Start / End Page

245 / 279

Location

United States

Related Subject Headings

  • Transcription Factors
  • Thioredoxins
  • Signal Transduction
  • Reactive Oxygen Species
  • Proto-Oncogene Mas
  • Prognosis
  • Oxidative Stress
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
An, N., & Kang, Y. (2014). Thioredoxin and hematologic malignancies. Adv Cancer Res, 122, 245–279. https://doi.org/10.1016/B978-0-12-420117-0.00007-4
An, Ningfei, and Yubin Kang. “Thioredoxin and hematologic malignancies.Adv Cancer Res 122 (2014): 245–79. https://doi.org/10.1016/B978-0-12-420117-0.00007-4.
An N, Kang Y. Thioredoxin and hematologic malignancies. Adv Cancer Res. 2014;122:245–79.
An, Ningfei, and Yubin Kang. “Thioredoxin and hematologic malignancies.Adv Cancer Res, vol. 122, 2014, pp. 245–79. Pubmed, doi:10.1016/B978-0-12-420117-0.00007-4.
An N, Kang Y. Thioredoxin and hematologic malignancies. Adv Cancer Res. 2014;122:245–279.

Published In

Adv Cancer Res

DOI

EISSN

2162-5557

Publication Date

2014

Volume

122

Start / End Page

245 / 279

Location

United States

Related Subject Headings

  • Transcription Factors
  • Thioredoxins
  • Signal Transduction
  • Reactive Oxygen Species
  • Proto-Oncogene Mas
  • Prognosis
  • Oxidative Stress
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Neoplasms